PTCHF OTC

PureTech Health plc operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts in the United States on the discovery, advancement, and market introduction of novel therapeutic solutions. The company's diverse pipeline targets a wide array of challenging medical conditions, including inflammatory, fibrotic, and immunological disorders, intractable cancers, various lymphatic and gastrointestinal issues, as well as neurological and neuropsychological ailments. Among its significant offerings, PureTech provides KarXT, a treatment designed to modulate muscarinic acetylcholine receptors for managing schizophrenia and the psychosis seen in Alzheimer's disease. Its technological foundations also encompass a regenerative biology platform applicable to conditions like androgenetic alopecia and epithelial aging, alongside an immunomodulation platform dedicated to addressing chronic and acute inflammatory disorders. Additionally, the firm develops oral therapies derived from specific bacterial consortia isolated from the human microbiome and treatments engineered to alleviate cognitive dysfunction associated with depression, multiple sclerosis, post-COVID and ICU recovery, and cancer-related conditions. Further innovations include hematopoietic stem cell-based therapies for individuals with blood cancer, a voice-activated technology platform capable of identifying health-related vocal shifts, and a proprietary system facilitating the oral delivery of biologics, vaccines, and other complex medications. In its robust development pipeline, PureTech is advancing LYT-100 for the treatment of lymphedema and other lymphatic flow anomalies, LYT-200 as an IgG4 monoclonal antibody targeting galectin-9, and LYT-210 for solid tumors. Pioneering technological frameworks under development include Glyph, a synthetic chemistry platform for lymphatic targeting; Orasome technology, which enables oral administration of large molecule therapeutic payloads; a meningeal lymphatics platform with implications for Alzheimer's and Parkinson's diseases; and the Alivio technology platform, designed for inflammation-targeted disease immunomodulation. PureTech Health plc has forged key collaboration and licensing agreements with leading pharmaceutical companies, including Boehringer Ingelheim International GMBH, Eli Lilly and Company, Imbrium Therapeutics L.P., and Shionogi & Co., Ltd. The company was founded in 2015 and maintains its corporate headquarters in Boston, Massachusetts.